Now showing items 1-1 of 1

    • Individualized dosing with axitinib: rationale and practical guidance. 

      Schmidinger, M; Danesi, R; Jones, R; McDermott, R; Pyle, L; Rini, B; Négrier, S (2018-04)
      Axitinib is a potent, selective, vascular endothelial growth factor receptor inhibitor with demonstrated efficacy as second-line treatment for metastatic renal cell carcinoma. Analyses of axitinib drug exposures have ...